PolyPid To Refile For IPO At A Company Value Of $80M

January 14, 2015 | The orthopedic pharmaceutical company PolyPid will revive its NASDAQ IPO, after it called off its previous offer in late 2014. The company published a revised prospectus to raised between $18-22 million, not including the underwriters’ commitment. The company hopes to reach a $80 million valuation in the IPO, with Aegis Capital acting as the chief underwriter along with Chardan Capital and MLV & Co. as secondary underwriters. PolyPid develops and markets a delayed-release treatment for compound bone fractures, which is scheduled to begin clinical trials in 2015, with hopes to enter the European market by 2017.